OROXINE

This brand name is authorized in Australia, Austria, Hong Kong SAR China, Ireland, Poland.

Active ingredients

The drug OROXINE contains one active pharmaceutical ingredient (API):

1	Levothyroxine UNII 9J765S329G - LEVOTHYROXINE SODIUM
	Levothyroxine sodium is used for the treatment of hypothyroidism. The chief action of levothyroxine is to increase the rate of cell metabolism.
	Read more about Levothyroxine

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
OROXINE Tablet	MPI, EU: SmPC	Health Products Regulatory Authority (IE)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
H03AA01	Levothyroxine sodium	H Systemic hormonal preparations, excl. Sex hormones and insulins → H03 Thyroid therapy → H03A Thyroid preparations → H03AA Thyroid hormones
Discover more medicines within H03AA01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	2173J, 2174K, 2175L, 9287T
HK	Department of Health Drug Office	57829, 57830, 57831
PL	Rejestru Produktów Leczniczych	100336553, 100336560, 100336576, 100336582, 100336599, 100336607, 100336620, 100336636, 100336642, 100336659, 100336665